Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease
Kernal Biologics, Inc., a venture-backed TechBio company pioneering novel therapeutics to program human cells directly inside the body, today announced that it has been awarded up to $48 million in funding by the Advanced Research Projects Agency for Health (ARPA-H). This project is to be funded by ARPA-H’s EMBODY program, which focuses on the engineering of immune cells inside the body. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D.
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to Lilly Gateway Labs (LGL) in Boston.
